

DHMH, Prevention and Health Promotion Administration
MADAP Advisory Board

Minutes—May 11, 2017 – Approved 7-28-17

Members Present: Rebecca Brotemarkle, PhD, ACRN, Jill Crank, CRNP, MSN/MPH, CDR Mathilda Fienkeng, PharmD, Daniel Hendricks, Morris Murray, Robyn Palmeiro, LCSW-C, David Posner, RPh, Douglas Rose, Janessa Smith, PharmD, BCPS, Leonard Sowah, MBChB, MPH, Diane Young, RN, MS, Jessica Rosen, MD, Sarah Rives Gray, MPH, MS, FNP-BC

Members Absent: Kareem A. Karara, PharmD, BCPS, CCHP, Jeanne C. Keruly, CRNP, Neha S. Pandit, PharmD, AAHIVP, BCPS, Robert Washington, PhD, MDiv.

Staff Present: Jeffrey Hitt, M.Ed., Mary Bahr, MGA, Arlette Lindsay, PA, Tanisha Carter

Guests Present: Dina Akbar, Bristol Myers Squibb, Lauren Linkenauer, Walgreens

Recorder: Tanisha Carter

Topic/ Issue	Discussion	Decisions/Assignments/Follow-up
1. Welcome and Introductions	Meeting was called to order by Chair, Mr. Jeffrey Hitt at 4:10 p.m. with a voting quorum present. He welcomed members and guests. Introductions were made around the room.	
2. Approval of the Minutes	Mr. Jeffrey Hitt asked the Board to review the November 10, 2016 minutes for any changes and/or corrections.	Missing from the minutes were brief discussions of adding Naloxone and hormonal medications to the Formulary. Both Naloxone and hormonal medications were addressed during this meeting. Motion by Diane Young, with Second by Douglas Rose, to approve the minutes as submitted. All in favor, no opposed, no abstention. Motion passed.
3. Bureau Updates	None	
4. MADAP Program Report	Ms. Mary Bahr, Center Chief for MADAP, reported that staff is working to streamline the eligibility process to make it easier for clients. In the future, applicants will submit only one more updated application. Then every 6 months thereafter clients will only need to verify their MADAP eligibility. MADAP is working with the Bureau's Surveillance Division to receive the	

Topic/ Issue	Discussion	Decisions/Assignments/Follow-up
	<p>client's CD4 and Viral Load test results into MADAP's client services system. This data feed will eliminate the need for the client's physician to complete and submit the MADAP medical form every year.</p> <p>MADAP helped over 1,500 clients during the 2017 Open Enrollment with on/off exchange plans. Drug utilization rate was 2% greater than the first quarter of last year. 100+ clients were added to MADAP+ for premium payments.</p>	
5. Progress Report on Hepatitis C Treatment	<p>Ms. Arlette Lindsay, Clinical Advisor, stated that since April 2016, MADAP had 25 clients approved for Hepatitis C treatment. The majority of clients approved were insured. MADAP is waiting to hear from Hepatitis and HIV Surveillance staff to finish working with CDC on a matching algorithm to renew efforts in finding reasons for low usage.</p>	
6. MADAP Formulary Updates	<p>Mr. Jeffrey Hitt reported approved additions to the MADAP Formulary from 11-10-16:</p> <p>Added provisionally while work continues on how to cover cost. These contraceptive devices are not carried by pharmacies and are implanted in physician office:</p> <ul style="list-style-type: none"> • Copper Intrauterine device (Paragard) • Etonogestral Implant (Nexplanon) <p>Added to formulary:</p> <ul style="list-style-type: none"> • Sofosbuvir/Velpatasvir (Epclusa) Antiviral – HCV • Ergocalciferol (Vitamin D) • Diabetic Testing Strips & Lancets 	
7. MADAP Formulary Discussion and Review	<p>Drugs added to the formulary as of 11-10-16 on interim approval by the Bureau's Director were Vemlidy (Antiviral HBV) and Menactra. The Board was requested for its recommendation on these two drugs.</p>	<p>Motion by Morris Murray, with Second by Jill Crank, to recommend the addition of Vemlidy and Menactra to the MADAP formulary. All in favor, no opposed, no abstention. Motion passes.</p>

Topic/ Issue	Discussion	Decisions/Assignments/Follow-up
8. MADAP Formulary Discussion and Review	<p>Ms. Janessa Smith, Pharm D, presented the following first group of medications which covers inhalation sprays and powders for COPD be considered for addition to the formulary:</p> <ul style="list-style-type: none"> • Indacaterol maleate (Arcapta Neohaler) • Tiotropium bromide-Olodaterol (Striverdi Respimat) • Olodaterol (Stiolto Respimat) • Glycopyrrolate-Formeterol fumarate (Bivespi Aerosphere) <p>Ms. Janessa Smith, Pharm D, also presented the following second group of medications - immunosuppressive agents be added to the formulary for transplant patients:</p> <ul style="list-style-type: none"> • Azathioprine (Imuran, Azasan) • Belatacept (Nulojix) • Cyclosporine (Sandimmune) • Cyclosporine modified (Neoral, Gengraf) • Everolimus (Zortress) • Mycophenolate mofetil (Cellcept) • Mycophenolate sodium (Myfortic) • Sirolimus (Rapamune) • Tacrolimus (Prograf) • Tacrolimus ext & prolonged (Astagraf XL, Envarsus XR) 	<p>Motion by Douglas Rose, with Second by David Posner to approve all drugs. All in favor, no opposed, no abstention. Motion passes.</p> <p>Motion David Posner, with Second by Leonard Sowah to approve all of the generic formulations of these drugs to be added to the MADAP formulary and to have a prior approval process for name brand drugs.</p> <p>Proposal by Mathilda Fienkeng to not allow these extra requirements because different formulations of some of these drugs are not bio-equivalent."</p> <p>Opposed by Morris Murray. Abstention by Robyn Palmeiro, Mathilda Fienkeng, and Jessica Rosen. Motion passed.</p>
	<p>Lastly, Ms. Janessa Smith, Pharm D, presented the following Hormonal Therapy, and Antifungal Agents be added to the formulary:</p> <ul style="list-style-type: none"> • Finasteride (Proscar) • Flutamide (Eulexin) • Estradiol transdermal (Climara, Alora) • Estradiol cypionate (Depo-Estradiol) • Estradiol valerate (Delestrogen) ** • Isavuconazonium Sulfate capsules (Cresemba) • Posaconazole (Noxafil) • Voriconazole (Vfend) 	<p>Motion by David Posner, with Second by Diane Young to approve all hormonal therapy including ** Estradiol valerate (Delestrogen) added by Jill Crank. All in favor, no opposed, no abstention. Motion passes.</p> <p>Motion Jill Crank, with Second by David Posner to the antifungal agents to MADAP formulary. All in favor, no opposed, no abstention. Motion passes.</p>

Topic/ Issue	Discussion	Decisions/Assignments/Follow-up
9. Other Business and Announcements	<p>The Board discussed and recommended adding Naloxone to the MADAP formulary.</p> <p>Ms. Mary Bahr announced recruitment for the one remaining Board vacancy to be filled by either a client or a community representative. Also starting in November 2017 meetings will occur on the first Thursday of November and May.</p>	Motion for Recommendation by Mathilda Fienkeng, with Second by Morris Murray to include the generic injection and nasal spray of <u>Naloxone</u> to the Formulary. All in favor, no opposed, no abstention. Motion passes.
10. Adjournment	Following a motion for adjournment, the meeting was adjourned by Mr. Jeffrey Hitt at 5:37 p.m.	Motion by David Posner, with Second by Diane Young, to adjourn the meeting. All in favor, no opposed, no abstention. Motion passes.
11. Approval of Minutes	On July 10, 2017, Ms. Mary Bahr sent the draft meeting minutes for May 11, 2017 to the MADAP Advisory Board members and requested approval of the minutes. Ms. Bahr conveyed that the first and second Board Member to respond with a yea vote would respectively be identified as the member making the motion to approve and the member who seconded the motion to approve. Each member was asked to reply to Ms. Bahr with a yea, nay or abstention. As of July 28, 2017, 15 out of 17 members had responded.	Motion by Leonard A. Sowah, with Second by Morris Murray, to approve these minutes as submitted. 13 favor, no opposed, 1 abstention, 1 member not voting, 2 members did not respond. Motion passed.

Dates of Upcoming MADAP Advisory Board Meetings:

October 26, 2017 (changed from November 2, 2017)

May 3, 2018

Meeting time: 4 – 5:30 pm

Minutes submitted by: Tanisha Carter